A risk based approach to defining protection levels within our facility in addition to the integrated application of scientific knowledge, technical innovation and quality risk management allows us to achieve high technology systems for the production of cytotoxics and cytostatic products, such as:

- standard sterile and oral formulations
- nano/micro emulsions
- nano/micro suspensions
- micellar formulations
- solvent based formulations

Homogenization, microfluidization, evaporation systems, disposable technologies, together with traditional equipment to handle standard process/products, enable BSP Pharmaceuticals to cover a wide range of processes/formulations.